ADVERTISEMENT

Sun Pharma - Leveraging Global Specialty Pipeline To Aid Growth: Nirmal Bang

In Q1, global specialty saw a sequential decline due to Levulan seasonality effect, which has normalised in Q2 FY24.

<div class="paragraphs"><p>A person pouring yellow pills into his hand from container. (Photo: freepik)</p></div>
A person pouring yellow pills into his hand from container. (Photo: freepik)
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
To continue reading this story
You must be an existing Premium User
OUR NEWSLETTERS
By signing up you agree to the Terms & Conditions of NDTV Profit